CYDY Company Profile

CYDY Time & Sales

CYDY Recent News

CYDY Filings

CYDY Financials

CYDY Buy Rating

Katangolo

07/13/2025 3:22:01 PM

Thanks again, Ohm. So does this mean

ohm20

07/13/2025 2:51:36 PM

the new MOA where LL primes cold (9)

Katangolo

07/13/2025 2:24:45 PM

All of this is true. I think what I was (3)

ohm20

07/13/2025 2:16:37 PM

This is why MARAVIROC Was sidelined. (9)

ohm20

07/13/2025 1:58:25 PM

FINAL DROP The One That Makes the (17)

Katangolo

07/13/2025 1:52:06 PM

Thank you for this that all makes

Katangolo

07/13/2025 1:50:33 PM

Thanks Ohm. That helped. This brings me

ohm20

07/13/2025 1:42:49 PM

What role does CXCR4 play in this? (9)

Katangolo

07/13/2025 1:42:35 PM

Thanks for this important tidbit. (3)

ohm20

07/13/2025 1:31:20 PM

I read it yet againso this is (14)

Rex47

07/13/2025 1:24:02 PM

Ironically Dr. Jay was the one who (11)

ohm20

07/13/2025 12:58:35 PM

Hiv-MDR pg 10: **...Leronlimab CCR5 RO (4)

ohm20

07/13/2025 12:53:40 PM

So, is it Leronlimab causes CD4 & CD8 (17)

Katangolo

07/13/2025 12:25:42 PM

Great stuff, RIZ and MY69Z! This is why (9)

Katangolo

07/13/2025 12:17:38 PM

Clearer for me as well. Thanks for the (1)

ohm20

07/13/2025 12:00:06 PM

USS, Ignoring the typos at (11)

chuckles759

07/13/2025 11:55:08 AM

I think My69z was partially correct (6)

Riztheinvestor

07/13/2025 11:43:07 AM

While they waited for the data, I (1)

Riztheinvestor

07/13/2025 11:07:02 AM

MY69 the most underrated poster and one (5)

Riztheinvestor

07/13/2025 11:03:27 AM

Exactly what youve seen for years (10)

My69z

07/13/2025 11:00:03 AM

Thx Kat to you & Riz.....also you said: (4)

My69z

07/13/2025 10:47:41 AM

Furthermore, the CCR5 RO assay (5)

Katangolo

07/13/2025 10:44:49 AM

DEEP pockets (2)

Katangolo

07/13/2025 10:43:50 AM

YESSS This is what I was getting out (6)

Katangolo

07/13/2025 10:39:58 AM

Thank you for clarifying and expanding. (5)

Riztheinvestor

07/13/2025 10:39:20 AM

Thanks Kat here is what I got. 1. What (14)

KenChowder

07/13/2025 10:15:38 AM

I think we had some collaboration with (4)

Mr3Putt

07/13/2025 9:58:07 AM

This P1 is a very public study (6)

My69z

07/13/2025 9:55:21 AM

Our CD4+ Tcells info came from our (4)

Katangolo

07/13/2025 8:51:11 AM

Mysterious Foundation Support . (2)

Katangolo

07/13/2025 8:49:39 AM

Agree, and so that binding to cold (1)

Katangolo

07/13/2025 8:47:28 AM

Im still reading through these (2)

Katangolo

07/13/2025 8:43:16 AM

Thanks Riz. Impressive. Immediate (3)

Katangolo

07/13/2025 8:21:31 AM

This is extremely intriguing. Thank (12)

KenChowder

07/13/2025 7:12:54 AM

The study financed by a mysterious (7)

SeeWhyDY

07/13/2025 6:13:31 AM

Alzheimers Disease - Phase 1 is (2)

My69z

07/13/2025 4:11:51 AM

From Google: In summary, CytoDyn's (6)

My69z

07/13/2025 3:50:08 AM

2019 paper: The ability of HIV-1 to (5)

Riztheinvestor

07/12/2025 10:36:43 PM

For NEW posters. Its been awhile. (7)

Riztheinvestor

07/12/2025 7:36:24 PM

You didnt just have my back. You (1)

My69z

07/12/2025 7:22:43 PM

The PD-1/PD-L1 pathway plays a (8)

sean007

07/12/2025 4:11:58 PM

Managed to get Most of $10K order (6)

Katangolo

07/12/2025 3:46:35 PM

I know youve got C2 in your back (4)

Riztheinvestor

07/12/2025 1:57:50 PM

Selective Release. You see it clear as (5)

SamaGong

07/12/2025 1:11:44 PM

Buc, yes, I think you are correct, and (10)

Plotinus

07/12/2025 11:22:34 AM

You are correct, it is an open label (11)

bucweey34

07/12/2025 11:06:04 AM

Samagong, Please correct me if Im (7)

MidnightRider

07/12/2025 10:42:29 AM

https://www.fiercepharma.com/pharma/wea (3)

SamaGong

07/12/2025 9:39:55 AM

USS, Ignoring the typos at (1)

USS JOHNSTON

07/11/2025 10:09:19 PM

Our prior management also 1. kept us (10)

Newer

Older

Recent Articles

• Snowflake's Mike Gannon Sparks SEC Filing After Influencer Talk
• Livestrong Foundation's Annual Challenge Empowers Cancer Survivors
• Google's Decision to Shift Women Techmakers Program Sparks Controversy
• Podiatry Content Connection Unveils Innovative AI Solutions
• zerohash Europe Gets MiCAR Authorization for Crypto Services
• Tech Titans' Dinner Sparks Fried Chicken Stock Boom
• The Rise of the Silver American Eagle: Why Stackers Are Going All In
• Tenaris Launches $600 Million in Share Buyback for Investors
• Kiyosaki Advocates for Bitcoin and Ethereum Amid Market Uncertainty
• Tenaris Launches $600 Million in Share Buybacks Amid Growth
• Exploring AI Adoption Among Small Businesses Across The U.S.
• Shiba Inu ETF Filing Sparks Significant Token Burn Event
• Investors of Avantor, Inc. Encouraged to Seek Justice Together
• Al Salam Bank Commemorates ASB Capital's Successful Year
• Tom Lee: The Trusted Face of Ethereum in the Finance World
• Elon Musk and Sam Altman: The Roadster Refund Debate
• Navigating Career Transitions: Insights from Industry Experts
• Key Steps for Fortinet, Inc. Investors Ahead of Class Action
• Air Traffic Controllers Face Staffing Crisis Amid Shutdown
• Warren Challenges Trump on Rising Costs Affecting Families
• James Hardie Industries Investors Invited to Join Critical Lawsuit
• Fluor Corporation's Investors Encouraged to Act Now for Justice
• Bitcoin Surges to $100K Amidst Market Challenges and Insights
• Ziegler Successfully Completes $44M Financing for Frasier
• Lowe's Contributes $1 Million for Hurricane Recovery in Jamaica
• Celebrate Dodgers' Triumph with New Era's 2025 Collection
• Richmond Terrace Capital Launches New €1.5 Billion Investment Fund
• Ameripath USA Collaborates with Recovery Resolutions to Support Recovery Housing
• Sequoia Capital Launches $950M Fund to Fuel AI Innovators
• Virginia Veterans Celebrate with Free Book Vouchers for Stories
• Innovative Advancements of Poain BlockEnergy in Global DeFi Market
• Investors of aTyr Pharma Should Secure Legal Help Now
• Bahrain Premieres Revolutionary Rooftop Solar Power Initiative
• Deqing's Pearl Mussel Award: A Mark of Agricultural Heritage
• Buck Sexton Unveils the Dawn of America’s Next Wealth Era
• Navigating the Promising Journey of Mutuum Finance and MUTM
• Belite Bio's Conditional Marketing Authorization Success for Tinlarebant
• Top Large-Cap Movers: Teradyne, Wayfair, and More Insights
• Top Stock Insights: Palantir's Surge and Pfizer's Struggles
• The Last Messages of Charlie Kirk Revealing His Fears
• Significant Stock Declines: Fiserv, eBay, and Garmin Under Pressure
• Major Moves in Tech: Earnings Reports & Market Trends Ahead
• Ford Faces Major Recall Challenges But Sees Opportunities Ahead
• Discover the Hidden Gems: Stocks Gaining Investor Interest
• OncoHost Showcases Innovative Insights in NSCLC Proteomics
• Mutuum Finance Gears Up for Exciting V1 Launch with $18M Raised
• Apple's Impressive Earnings, Bold Future Predictions Unveiled
• Fangzhou's Innovative AI Solutions Transform Chronic Care Management
• Fangzhou Innovates Chronic Disease Management with AI Solutions
• CoorsTek Bioceramics Triumphs in Legal Right to Market Hip Components